Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10

被引:3
|
作者
Kong, L. M.
Qian, M. R. [2 ]
Hu, H. H.
Xu, S. Y.
Yu, L. S.
Jiang, H. D.
Chen, S. Q.
Zeng, S. [1 ]
机构
[1] Zhejiang Univ, Dept Pharmaceut Anal & Drug Metab, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Acad Agr Sci, Inst Qual Stand Agr Prod, Hangzhou, Zhejiang, Peoples R China
来源
PHARMAZIE | 2012年 / 67卷 / 05期
关键词
IN-VITRO; CYP2D6; METABOLISM; PROPRANOLOL; IMIPRAMINE; EXPRESSION; ENZYMES; CYP1A2; SYSTEM;
D O I
10.1691/ph.2012.1128
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Polymorphisms of the cytochrome P450 2D6 (CYP2D6) gene play a major role in pharmacokinetic variability in human, while CYP2D6*10 is an important subtype in Asian people. In this study, the co-expression enzyme of human recombinant CYPOR, CYPb5 and CYP2D6.1 or CYP2D6.10 with the Bac-to-Bac (TM) system in baculovirus-infected insect cells was used to study the catalytical activity to imipramine metabolism and stereoselective metabolism of propranolol. The metabolites of imipramine were identified of hydroxyl imipramine and desipramine by LC-MS/MS. There are some differences between CYP2D6.1 and CYP2D6.10 activity. The kinetics parameters K-m, V-max, and CLint are 11.77 +/- 0.91 mu mol/L, 0.4235 +/- 0.05 nmol/nmol CYP2D6.1/min and 3.60 x 10(-5) ml/min/nmol CYP2D6.1 (n = 3) for CYP2D6.1, respectively, and 9.05 +/- 0.87 mu mol/L, 0.42 +/- 0.03 nmol/nmol CYP2D6.10/min, and 4.60 x 10(-5) ml/min/nmol CYP2D6.10 (n = 3) for CYP2D6.10. For propranolol, two metabolites were identified to be hydroxyl and N-desisopropylation propranolol by LC-MS/MS. When the substrate concentration was 0.20 mu mol/L, CYP2D6.1 and CYP2D6.10 exhibited significant stereoseletivity. Furthermore, enan-tioselective formation has been detected. Both of CYP2D6.1 and CYP2D6.10 produced more hydroxyl propranolol from the R-(+)-isomer than from the S-(-)-isomer while there was no obvious difference for N-desisopropylation propranolol production between R-(+)- and S-(-)- isomer. In summary, there is a some-what different catalytical activity and stereoselectivity between the human recombinant CYP2D6.1 and CYP2D6.10. The data we got will be helpful in preclinical research and clinical use of CYP2D6 substrates.
引用
收藏
页码:440 / 447
页数:8
相关论文
共 50 条
  • [1] A Comparison of Non- Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
    He, Zhi-Xu
    Chen, Xiao-Wu
    Yang, Yinxue
    Zhou, Shu-Feng
    CURRENT DRUG METABOLISM, 2016, 17 (06) : 520 - 527
  • [2] Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation
    Niwa, Toshiro
    Sasaki, Shoko
    Yamamoto, Yuka
    Tanaka, Mayu
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (05) : 741 - 747
  • [3] Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat Bound
    Wang, An
    Savas, Uzen
    Hsu, Mei-Hui
    Stout, C. David
    Johnson, Eric F.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (14) : 10834 - 10843
  • [4] Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6
    Uehara, Shotaro
    Murayama, Norie
    Yamazaki, Hiroshi
    Suemizu, Hiroshi
    XENOBIOTICA, 2019, 49 (11) : 1323 - 1331
  • [5] Comparison of Cytochrome P450 2D6 and Variants in Terms of Drug Oxidation Rates and Substrate Inhibition
    Niwa, Toshiro
    Murayama, Norie
    Yamazaki, Hiroshi
    CURRENT DRUG METABOLISM, 2011, 12 (05) : 412 - 435
  • [6] Molecular Dynamics Simulations to Investigate the Influences of Amino Acid Mutations on Protein Three-Dimensional Structures of Cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62
    Fukuyoshi, Shuichi
    Kometani, Masaharu
    Watanabe, Yurie
    Hiratsuka, Masahiro
    Yamaotsu, Noriyuki
    Hirono, Shuichi
    Manabe, Noriyoshi
    Takahashi, Ohgi
    Oda, Akifumi
    PLOS ONE, 2016, 11 (04):
  • [7] Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants
    Youdim, K.
    Dodia, R.
    XENOBIOTICA, 2010, 40 (04) : 235 - 244
  • [8] Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers
    Wilner, KD
    Demattos, SB
    Anziano, RJ
    Apseloff, G
    Gerber, N
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 43S - 47S
  • [9] Quantitation of Human Cytochrome P450 2D6 Protein with Immunoblot and Mass Spectrometry Analysis
    Yu, Ai-Ming
    Qu, Jun
    Felmlee, Melanie A.
    Cao, Jin
    Jiang, Xi-Ling
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (01) : 170 - 177
  • [10] Potential of decursin to inhibit the human cytochrome P450 2J2 isoform
    Lee, Boram
    Wu, Zhexue
    Sung, Sang Hyun
    Lee, Taeho
    Song, Kyung-Sik
    Lee, Min Young
    Liu, Kwang-Hyeon
    FOOD AND CHEMICAL TOXICOLOGY, 2014, 70 : 94 - 99